Sickle Cell Trait (SCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Sickle Cell Trait (SCT) Market Outlook

Thelansis’s “Sickle Cell Trait (SCT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sickle Cell Trait treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sickle Cell Trait (SCT) Overview

The sickle cell trait represents a hereditary hematological anomaly characterized by a single abnormal allele of the hemoglobin beta gene. This contrasts with sickle cell disease, where both alleles are abnormal. Individuals with sickle cell trait typically exhibit no symptomatic manifestations related to sickling and thus generally experience an improved quality of life compared to sickle cell disease patients. Notably, individuals possessing the sickle cell trait do not demonstrate an elevated mortality risk relative to the general populace. This discourse delves into the assessment and treatment of sickle cell trait, emphasizing the collaborative efforts of the interdisciplinary team in enhancing the care provided to affected individuals. The genetic basis of the sickle cell trait is rooted in an atypical hemoglobin variant termed sickle hemoglobin (Hb S), resulting from a point mutation in the beta-globin chain. This genetic alteration entails a nucleotide substitution where thymine replaces adenine at codon 6 of the beta hemoglobin chain. This substitution subsequently prompts the amino acid sequence conversion from glutamic acid to valine. This valine-based hemoglobin variant renders red blood cells susceptible to assuming a sickle shape under reduced oxygen levels. Individuals harboring sickle cell trait inherit one Hb S allele from one parent and one normal HbA allele from the other, conferring a heterozygous genetic makeup. It is generally not associated with frequent vaso-occlusive crises, a characteristic feature of sickle cell disease. However, individuals with sickle cell trait may exhibit analogous clinical presentations to sickle cell anemia if exposed to circumstances conducive to sickling. Such conditions encompass profound hypoxia, dehydration, heightened sympathetic activity, temperature extremes, elevated 2,3-diphosphoglycerate (2,3-DPG) levels, and immune cell release. The presence of Hb S precipitates the occlusion of minute capillaries, particularly within the osseous structures, by sickled erythrocytes. Concurrently, other cellular elements, including inflammatory cells and platelets, contribute to escalated adhesion of the sickled red blood cells. This pathological process can potentially unfold across multiple organ systems, encompassing the thoracic region, cardiac structures, pulmonary tissue, abdominal organs, kidneys, and peripheral extremities. Cumulative ischemic events stemming from these occurrences may lead to chronic organ damage. Sickle cell trait exhibits a higher prevalence within specific ethnic groups, such as:

• African Americans (with approximately 8 to 10 percent carrying the sickle cell trait)
• Hispanics
• South Asians
• Caucasians hailing from southern Europe
• Individuals originating from Middle Eastern nations

Differential diagnostic considerations for sickle cell trait encompass various forms of sickle cell disease, beta-thalassemia major, and beta-thalassemia minor. While sickle cell trait has been associated with various complications, including papillary necrosis, asymptomatic bacteriuria, splenic infarction, and exercise-induced fatality, the prognosis for individuals with sickle cell trait is generally favorable. It is pertinent to acknowledge that sickle cell trait is an inheritable hematologic anomaly affecting many Americans, with estimates ranging from one to three million individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: